{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:44:55Z","timestamp":1793407495562,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"The Innovative Health Initiative Joint Undertaking","award":["101112145"],"award-info":[{"award-number":["101112145"]}]},{"DOI":"10.13039\/501100001858","name":"VINNOVA","doi-asserted-by":"publisher","award":["2021-02680"],"award-info":[{"award-number":["2021-02680"]}],"id":[{"id":"10.13039\/501100001858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018163","name":"Margareta af Ugglas Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018163","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2024-03573"],"award-info":[{"award-number":["2024-03573"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2023-00356"],"award-info":[{"award-number":["2023-00356"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-01018"],"award-info":[{"award-number":["2022-01018"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2019-02397"],"award-info":[{"award-number":["2019-02397"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2019-02075"],"award-info":[{"award-number":["2019-02075"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2019-02075_15"],"award-info":[{"award-number":["2019-02075_15"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Swedish Brain Foundation","doi-asserted-by":"crossref","award":["FO2024-0287"],"award-info":[{"award-number":["FO2024-0287"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003792","name":"Swedish Brain Foundation","doi-asserted-by":"crossref","award":["FO2024-0097"],"award-info":[{"award-number":["FO2024-0097"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003792","name":"Swedish Brain Foundation","doi-asserted-by":"crossref","award":["FO2024-0339"],"award-info":[{"award-number":["FO2024-0339"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Union\u2019s Horizon Europe research and innovation programme","award":["101053962"],"award-info":[{"award-number":["101053962"]}]},{"name":"Swedish State Support for Clinical Research","award":["ALFGBG-71320"],"award-info":[{"award-number":["ALFGBG-71320"]}]},{"name":"Swedish State Support for Clinical Research","award":["ALFGBG-81392"],"award-info":[{"award-number":["ALFGBG-81392"]}]},{"name":"Swedish State Support for Clinical Research","award":["ALFGBG-771071"],"award-info":[{"award-number":["ALFGBG-771071"]}]},{"name":"Swedish State Support for Clinical Research","award":["ALFGBG-1005471"],"award-info":[{"award-number":["ALFGBG-1005471"]}]},{"name":"Swedish State Support for Clinical Research","award":["ALFGBG-965923"],"award-info":[{"award-number":["ALFGBG-965923"]}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["AF-842471"],"award-info":[{"award-number":["AF-842471"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["AF-737641"],"award-info":[{"award-number":["AF-737641"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["AF-929959"],"award-info":[{"award-number":["AF-929959"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["AF-939825"],"award-info":[{"award-number":["AF-939825"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008587","name":"Stiftelsen Psykiatriska Forskningsfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["2024-03599"],"award-info":[{"award-number":["2024-03599"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the regional agreement on medical training and clinical research between the Stockholm County council and the Karolinska Institutet"},{"name":"Paulsson foundation"},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40273-025-01527-7","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T19:05:50Z","timestamp":1753815950000},"page":"1251-1266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Cost-Effective Price of Lecanemab for Patients with Early Alzheimer\u2019s Disease in Sweden"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8101-0563","authenticated-orcid":false,"given":"Xin","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandar","family":"Aye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Frisell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Aho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Handels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Wimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Winblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Eriksdotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias Borgh","family":"Skillb\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"1527_CR1","doi-asserted-by":"crossref","unstructured":"2024 Alzheimer's disease facts and figures. Alzheimers Dement. 2024;20(5):3708-821.","DOI":"10.1002\/alz.13809"},{"issue":"7","key":"1527_CR2","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1002\/alz.12901","volume":"19","author":"A Wimo","year":"2023","unstructured":"Wimo A, Seeher K, Cataldi R, Cyhlarova E, Dielemann JL, Frisell O, et al. The worldwide costs of dementia in 2019. Alzheimers Dement. 2023;19(7):2865\u201373.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1527_CR3","doi-asserted-by":"publisher","first-page":"15369","DOI":"10.1007\/s40273-024-01443-2","volume":"43","author":"S Aye","year":"2025","unstructured":"Aye S, Frisell O, Zetterberg H, Skillback TB, Kern S, Eriksdotter M, et al. Costs of care in relation to Alzheimer\u2019s disease severity in Sweden: a national registry-based cohort study. Pharmacoeconomics. 2025;43(2):15369.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"1527_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1001\/jamainternmed.2023.8522","volume":"184","author":"DB Reuben","year":"2024","unstructured":"Reuben DB, Kremen S, Maust DT. Dementia prevention and treatment: a narrative review. JAMA Intern Med. 2024;184(5):563\u201372.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"1527_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"1527_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01441-8","volume":"16","author":"LS Honig","year":"2024","unstructured":"Honig LS, Sabbagh MN, van Dyck CH, Sperling RA, Hersch S, Matta A, et al. Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease. Alzheimers Res Ther. 2024;16(1): 105.","journal-title":"Alzheimers Res Ther"},{"key":"1527_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100657","volume":"29","author":"L Jonsson","year":"2023","unstructured":"Jonsson L, Wimo A, Handels R, Johansson G, Boada M, Engelborghs S, et al. The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer\u2019s disease: an EADC-EC viewpoint. Lancet Reg Health Eur. 2023;29: 100657.","journal-title":"Lancet Reg Health Eur."},{"issue":"7","key":"1527_CR8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209218","volume":"102","author":"HV Nguyen","year":"2024","unstructured":"Nguyen HV, Mital S, Knopman DS, Alexander GC. Cost-effectiveness of lecanemab for individuals with early-stage Alzheimer disease. Neurology. 2024;102(7): e209218.","journal-title":"Neurology"},{"key":"1527_CR9","unstructured":"Lin G, Whittington M, Wright A, Agboola F, Herron-Smith S, Pearson S, et al. Beta-amyloid antibodies for early Alzheimer\u2019s disease: effectiveness and value; evidence report. Inst Clin Econ Rev. 2023. https:\/\/icer.org\/assessment\/alzheimers-disease-2022\/#timeline."},{"issue":"3","key":"1527_CR10","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40120-022-00373-5","volume":"11","author":"AA Tahami Monfared","year":"2022","unstructured":"Tahami Monfared AA, Tafazzoli A, Chavan A, Ye W, Zhang Q. The potential economic value of lecanemab in patients with early Alzheimer\u2019s disease using simulation modeling. Neurol Ther. 2022;11(3):1285\u2013307.","journal-title":"Neurol Ther"},{"issue":"4","key":"1527_CR11","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s40120-023-00492-7","volume":"12","author":"A Igarashi","year":"2023","unstructured":"Igarashi A, Azuma MK, Zhang Q, Ye W, Sardesai A, Folse H, et al. Predicting the societal value of lecanemab in early Alzheimer\u2019s disease in Japan: a patient-level simulation. Neurol Ther. 2023;12(4):1133\u201357.","journal-title":"Neurol Ther."},{"issue":"3","key":"1527_CR12","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s40120-023-00460-1","volume":"12","author":"AA Tahami Monfared","year":"2023","unstructured":"Tahami Monfared AA, Ye W, Sardesai A, Folse H, Chavan A, Kang K, et al. Estimated societal value of lecanemab in patients with early Alzheimer\u2019s disease using simulation modeling. Neurol Ther. 2023;12(3):795\u2013814.","journal-title":"Neurol Ther"},{"key":"1527_CR13","unstructured":"National Institute for Health and Care Excellence. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer\u2019s disease. London: NICE; 2024. https:\/\/www.nice.org.uk\/guidance\/gid-ta11220\/documents\/committee-papers."},{"issue":"4","key":"1527_CR14","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1177\/13872877251323231","volume":"104","author":"A Wimo","year":"2025","unstructured":"Wimo A, Handels R, Blennow K, Kirsebom KB, Selnes P, Bon J, et al. Cost-effectiveness of diagnosing and treating patients with early Alzheimer\u2019s disease with anti-amyloid treatment in a clinical setting. J Alzheimers Dis. 2025;104(4):1167\u201384.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"1527_CR15","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40258-024-00878-0","volume":"22","author":"MG Darab","year":"2024","unstructured":"Darab MG, Engel L, Henzler D, Lauerer M, Nagel E, Brown V, et al. Model-based economic evaluations of interventions for dementia: an updated systematic review and quality assessment. Appl Health Econ Health Policy. 2024;22(4):503\u201325.","journal-title":"Appl Health Econ Health Policy"},{"issue":"2","key":"1527_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116538","volume":"10","author":"D Religa","year":"2015","unstructured":"Religa D, Fereshtehnejad SM, Cermakova P, Edlund AK, Garcia-Ptacek S, Granqvist N, et al. Svedem, the Swedish dementia registry \u2013 a tool for improving the quality of diagnostics, treatment and care of dementia patients in clinical practice. PloS\u00a0One. 2015;10(2): e0116538.","journal-title":"PloS\u00a0One"},{"issue":"7","key":"1527_CR17","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1177\/14034948211061016","volume":"50","author":"AC Meyer","year":"2022","unstructured":"Meyer AC, Sandstrom G, Modig K. Nationwide data on home care and care home residence: presentation of the Swedish Social Service Register, its content and coverage. Scand J Public Health. 2022;50(7):946\u201358.","journal-title":"Scand J Public Health"},{"issue":"7","key":"1527_CR18","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register\u2013opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726\u201335.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1527_CR19","unstructured":"Socialstyrelsen. Statistical register's production and quality National Patient Register 2022. https:\/\/www.socialstyrelsen.se\/en\/statistics-and-data\/registers\/national-patient-register."},{"issue":"9","key":"1527_CR20","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","volume":"32","author":"HL Brooke","year":"2017","unstructured":"Brooke HL, Talb\u00e4ck M, H\u00f6rnblad J, Johansson LA, Ludvigsson JF, Druid H, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32(9):765\u201373.","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"1527_CR21","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362\u201377.","journal-title":"J Prev Alzheimers Dis."},{"key":"1527_CR22","unstructured":"Socialstyrelsen. V\u00e5rd och omsorg vid demenssjukdom \u2013 Sammanfattning med f\u00f6rb\u00e4ttringsomr\u00e5den. 2018. https:\/\/www.socialstyrelsen.se\/publikationer\/nationella-riktlinjer--vard-och-omsorg-vid-demenssjukdom--utvardering-2018--sammanfattning-med-forbattringsomraden-2018-3-1."},{"issue":"1","key":"1527_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01124-2","volume":"14","author":"E McDade","year":"2022","unstructured":"McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M, et al. Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022;14(1): 191.","journal-title":"Alzheimers Res Ther"},{"key":"1527_CR24","unstructured":"Sperling R, Selkoe D, Reyderman L, Youfang C, Van Dyck C, editors. Does the current evidence base support lecanemab continued dosing for early Alzheimer's Disease?. Alzheimer's Association International Conference; Philadelphia, PA; 2024. https:\/\/www.eisai.com\/ir\/library\/presentations\/pdf\/4523_240731_1.pdf."},{"issue":"2","key":"1527_CR25","doi-asserted-by":"publisher","first-page":"320","DOI":"10.14283\/jpad.2024.28","volume":"11","author":"J Chandler","year":"2024","unstructured":"Chandler J, Georgieva M, Desai U, Done N, Gomez-Lievano A, Ye W, et al. Impact of differential rates of disease progression in amyloid-positive early Alzheimer\u2019s disease: findings from a longitudinal cohort analysis. J Prev Alzheimers Dis. 2024;11(2):320\u20138.","journal-title":"J Prev Alzheimers Dis."},{"issue":"1","key":"1527_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-024-04796-7","volume":"24","author":"K Schmidt-Mende","year":"2024","unstructured":"Schmidt-Mende K, Arvinge C, Cioffi G, Gustafsson LL, Modig K, Meyer AC. Profiling chronic diseases and hospitalizations in older home care recipients: a nationwide cohort study in Sweden. BMC Geriatr. 2024;24(1): 312.","journal-title":"BMC Geriatr"},{"issue":"12","key":"1527_CR27","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1016\/j.jval.2022.09.1686","volume":"25","author":"J Viollet","year":"2022","unstructured":"Viollet J, O\u2019Leary E, Camacho Gonzalez C, Lauppe R, Oldsberg L. HTA228 willingness to pay for different severity levels in Sweden: an analysis of TLV decisions (2014\u20132022). Value Health. 2022;25(12):S341.","journal-title":"Value Health."},{"issue":"12","key":"1527_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.18637\/jss.v081.i12","volume":"81","author":"C Anderson-Bergman","year":"2017","unstructured":"Anderson-Bergman C. icenReg: regression models for interval censored data in R. J Stat Softw. 2017;81(12):123.","journal-title":"J Stat Softw"},{"issue":"10","key":"1527_CR29","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/j.jamda.2020.12.040","volume":"22","author":"A Marengoni","year":"2021","unstructured":"Marengoni A, Tazzeo C, Calderon-Larranaga A, Roso-Llorach A, Onder G, Zucchelli A, et al. Multimorbidity patterns and 6-year risk of institutionalization in older persons: the role of social formal and informal care. J Am Med Dir Assoc. 2021;22(10):2184\u20139 (e1).","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"1527_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01053-0","volume":"14","author":"A Mank","year":"2022","unstructured":"Mank A, van Maurik IS, Rijnhart JJM, Bakker ED, Bouteloup V, Le Scouarnec L, et al. Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14(1): 110.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1527_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/gerona\/63.1.56","volume":"63","author":"KH Pitkala","year":"2008","unstructured":"Pitkala KH, Laurila JV, Strandberg TE, Kautiainen H, Sintonen H, Tilvis RS. Multicomponent geriatric intervention for elderly inpatients with delirium: effects on costs and health-related quality of life. J Gerontol A Biol Sci Med Sci. 2008;63(1):56\u201361.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1527_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-6-84","volume":"6","author":"B Nafees","year":"2008","unstructured":"Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6: 84.","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"1527_CR33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jval.2024.07.009","volume":"28","author":"R Handels","year":"2024","unstructured":"Handels R, Herring WL, Grimm S, Skoldunger A, Winblad B, Wimo A, et al. New International Pharmaco-Economic Collaboration on Alzheimer\u2019s Disease (IPECAD) open-source model framework for the health technology assessment of early Alzheimer\u2019s disease treatment: development and use cases. Value Health. 2024;28(4):511\u20138.","journal-title":"Value Health."},{"issue":"1","key":"1527_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00723-1","volume":"12","author":"F Landeiro","year":"2020","unstructured":"Landeiro F, Mughal S, Walsh K, Nye E, Morton J, Williams H, et al. Health-related quality of life in people with predementia Alzheimer\u2019s disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review. Alzheimers Res Ther. 2020;12(1): 154.","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"1527_CR35","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","volume":"15","author":"B Winblad","year":"2016","unstructured":"Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, et al. Defeating Alzheimer\u2019s disease and other dementias: a priority for European science and society. Lancet Neurol. 2016;15(5):455\u2013532.","journal-title":"Lancet Neurol"},{"issue":"7","key":"1527_CR36","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jalz.2019.06.001","volume":"15","author":"V Hachinski","year":"2019","unstructured":"Hachinski V, Einhaupl K, Ganten D, Alladi S, Brayne C, Stephan BCM, et al. Preventing dementia by preventing stroke: The Berlin Manifesto. Alzheimers Dement. 2019;15(7):961\u201384.","journal-title":"Alzheimers Dement"},{"issue":"25","key":"1527_CR37","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1016\/j.jacc.2019.04.034","volume":"73","author":"C Iadecola","year":"2019","unstructured":"Iadecola C, Duering M, Hachinski V, Joutel A, Pendlebury ST, Schneider JA, et al. Vascular cognitive impairment and dementia: JACC scientific expert panel. J Am Coll Cardiol. 2019;73(25):3326\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1527_CR38","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/jnnp.2010.231555","volume":"82","author":"LS Elias-Sonnenschein","year":"2011","unstructured":"Elias-Sonnenschein LS, Viechtbauer W, Ramakers IH, Verhey FR, Visser PJ. Predictive value of APOE-epsilon4 allele for progression from MCI to AD-type dementia: a meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82(10):1149\u201356.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1527_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14467","volume":"21","author":"D Andrews","year":"2025","unstructured":"Andrews D, Ducharme S, Chertkow H, Sormani MP, Collins DL. Alzheimer\u2019s Disease Neuroimaging I. The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect. Alzheimers Dement. 2025;21(1): e14467.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1527_CR40","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/joim.13759","volume":"295","author":"K Wahlberg","year":"2024","unstructured":"Wahlberg K, Winblad B, Cole A, Herring WL, Ramsberg J, Torontali I, et al. People get ready! A new generation of Alzheimer\u2019s therapies may require new ways to deliver and pay for healthcare. J Intern Med. 2024;295(3):281\u201391.","journal-title":"J Intern Med"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01527-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01527-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01527-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:51:50Z","timestamp":1758361910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01527-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1527"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01527-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"assertion":[{"value":"15 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received approval from the Swedish Ethical Review Authority (DNR: 2024-07272-02). Ethical approvals for NACC were obtained from the local institutional review boards at each participating site. The NACC request ID for this study is 11753.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Statements"}},{"value":"In accordance with Swedish regulations, we are unable to share the data used in this study. Researchers can access SveDem and other Swedish registers after receiving ethical approvals from ethical review authorities and approvals from the register holders. Analysis codes for the study, including codes for the meta-analyses of utility, are available at: .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Sharing"}},{"value":"All authors, including AW and BW, have reviewed the manuscript, provided critical feedback, and approved the submission of the manuscript for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"RH has received consulting fees in the past 36 months from Lilly Nederland and the Institute for Medical Technology Assessment (paid to institution), outside this study. BW has served on scientific advisory boards for Alzinova, Axon Neuroscience, Artery Therapeutics, NSC-Therapeutics, and Phanes Biotech and on a data safety monitoring board for Primus-AD. SK has served on scientific advisory boards and as a speaker and\/or consultant for Roche, Eli Lilly, Geras Solutions, Optoceutics, Biogen, Eisai, Merry Life, Triolab, Novo Nordisk, and Bioarctic, unrelated to the present study content. HZ has served on scientific advisory boards and\/or as a consultant for AbbVie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside the submitted work). LJ has received research grants (unrelated to the current work) from Novo Nordisk; consultancy fees from Lundbeck, Eli Lilly, and Teva; and licence fees for the RUD (resource utilization in dementia) instrument. LJ is an editorial board member of PharmacoEconomics and was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions. AW and BW have received licence fees for the RUD instrument. ME has served as consultant for BioArctic AB, Roche, Eli Lilly, Biogen\/Eisai, and Novo Nordisk and given lectures in symposia sponsored by Roche. XX, SA, OF, EA, YL, and TS have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Open access funding provided by Karolinska Institute. This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement no. 101112145 and PREDEM (Vinnova grant 2021-02680). The JU receives support from the European Union\u2019s Horizon Europe research and innovation programme, Combinostics Oy and BioArctic AB. The views and opinions expressed are those of the authors and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them. BW has received research funding from Margaretha af Ugglas\u2019 foundation, Swedish Research Council (2024-03573), and Swedish Brain Foundation (FO2024-0287). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356, #2022-01018 and #2019-02397), the European Union\u2019s Horizon Europe research and innovation programme under grant agreement no. 101053962, and Swedish State Support for Clinical Research (#ALFGBG-71320). SK was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALFGBG-1005471, ALFGBG-965923, ALFGBG-81392, ALFGBG-771071), the Alzheimerfonden (AF-842471, AF-737641, AF-929959, AF-939825), the Swedish Research Council (2019-02075, 2019-02075_15), Stiftelsen Psykiatriska Forskningsfonden, and the Swedish Brain Foundation (FO2024-0097). ME was supported by the Swedish Research Council (2024-03599), the Swedish Brain Foundation (FO2024-0339), the regional agreement on medical training and clinical research between the Stockholm County council and the Karolinska Institutet (ALF) and the Paulsson foundation.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}